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Figure 2 Comparison of the candidate regions on chromosome
2q11-q13 for autosomal dominant (AD) and recessive (AR) ectodermal
dysplasia. The order of the principal markers used in the study and
the distances are those of the Marshfield sex-averaged chromosome 2
linkage map. Since loci D2S135 and D2S1321 are very close to each
other, only D2S135 appears in the figure.
Genome Research, http://www-genome.wi.mit.edu (for
marker order in the 2q11-q13 region)
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Mosaicism and Sporadic Familial Adenomatous
Polyposis
To the Editor:
Familial adenomatous polyposis (FAP [MIM 175100])
is an autosomal dominant heritable disorder caused
by germ-line mutations in the APC gene (M74088
[GenBank]). There is a high new-mutation rate, with
∼25% of all cases being sporadic (Bisgaard et al. 1994).
Parental mosaicism can explain newmutations in genetic
disorders (Hall 1988), whereas germ-line and/or somatic
mosaicism has been described in genes associated with
tumors such as p53 (Kovar et al. 1992), Rb1 (Greger et
al. 1990; Lohmann et al. 1997), NF1 (La´zaro et al.
1995), and NF2 (Bourn et al. 1994). We were interested
to determine whether APC-gene mutational mosaicism
could account for some of the apparentlynew” APCmu-
tations. Systematic studies of our registry identified five
in which a germ-line mutation was established (Prosser
et al. 1994), parental leukocyte DNA was available, and
paternity was assured. These five patients were the sub-
jects of detailed studies to determine the level of parental
APC mutational mosaicism (table 1).
During S35 sequencing of parental blood-leukocyte
DNA samples from the first sporadic FAP case, we noted
a faint mutant allele that was reproducible on repeated
analyses. The clinical history of this sporadic FAP patient
(patient 17) is noteworthy. Dense distal colonic poly-
posis was diagnosed at age 22 years, with three distinct
carcinomas and myriads of smaller polyps, many of
which showed carcinomatous change. Mastectomy was
required for breast carcinoma when the patient was age
37 years, and disseminated ovarian cancer resulted in
death at age 44 years. Her mother (patient 16) had a
mastectomy for breast carcinoma at age 46 years, was
negative in a screen for colonic polyps when she was
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Table 1
APC Mutations and Parental-Mosaicism Screening Strategy for Sporadic FAP Patients
Patient Nucleotide Change Effect on Coding Sequence Parental-Mosaicism Screening Assay
17 1354delGT Frameshift S35 sequencing, color-selective and nonselective PCR, cloning
148 694CrT Argrstop at 232 Mutation-specific restriction digestion and PCR enrichment
410 4192GrT Glurstop at 1398 PCR cloning, single-cell analysis
893 3926delAAAAG Frameshift PCR cloning
1024 4135CrT Glnrstop at 1379 Single-cell analysis
NOTE.—In all cases, a heterozygous mutation was excluded by standard analysis of parental leukocyte DNA, and paternity
was assured. A description of each assay can be obtained from the corresponding author.
age 64 years, and subsequently died from ovarian cancer
at age 67 years. There was an extensive family history
of breast cancer due to a BRCA1 mutation (5382insC
mutation [Mullen et al. 1997]), with several cases of
gastric and colon cancer in the extended family. Patient
17 carried the 5382insC BRCA1 mutation, as well as
an APC mutation (table 1).
The APC mutation identified in patient 17 was within
a simple repeat region, a GT deletion in a run of four
GT dinucleotides in exon 10 (table 1). On observing the
faint mutant allele in the maternal leukocyte-DNA sam-
ple (patient 16), we were first concerned that it might
represent sample contamination by leukocyte DNA of
patient 17. However, sequencing of two other samples
from patient 16 that had been taken several years apart
confirmed the faint mutant allele, and we never saw this
sequence in paternal or control leukocyte DNAs. To ex-
clude the possibility that the mutant sequence was due
to PCR error, we devised a PCR cloning strategy that
reduced the number of PCR cycles and allowed easy
identification of bacterial clones carrying the 1354delGT
allele. We designed PCR primers for cloning into
pBluescript that were out of frame for wild-type se-
quence and in frame for b-galactosidase in the presence
of the patient 17 APC mutation (details are available
from the corresponding author, on request). This gave
blue colonies for mutant alleles and white colonies for
the wild type.
Plating of PCR clones derived from patient 17 gave
the expected 50% blue colonies. Ten blue colonies were
picked at random and were sequenced, confirming the
1354delGT allele in every clone. All 10 white colonies
picked were wild-type sequence, as expected. The blue:
white colony ratio was substantially lower in clones de-
rived either from patient 16 or from control DNAs, typ-
ically !10% blue colonies in replicate PCR cloning ex-
periments. Approximately 60% of blue clones derived
from patient 16 and from control DNA were due to
plasmid rearrangements. However, sequencing of 37
blue clones with the correct-size PCR insert from patient
16 DNA identified eight alleles that were identical to the
1354delGT mutation in patient 17 (fig. 1), demonstrat-
ing the utility of our PCR cloning–enrichment strategy.
Although some blue colonies were due to plasmid re-
arrangements, mutant sequence was never identified in
any clones derived from control DNA, in multiple
experiments.
To formally quantify the level of mosaicism in blood
leukocytes, PCR amplification products from patients 16
and 17 and from control leukocyte-DNA templates were
cloned without selection for color. Mutation screening
using heteroduplex analysis of 41 clones that contained
the correct-size insert derived from patient 17 DNA tem-
plates gave 21 mutant and 20 wild-type alleles. For pa-
tient 16’s leukocyte DNA, 310 colonies were picked, and
113 contained the correct-size APC fragment, 4 (3.5%)
of which were 1354delGT mutant alleles. Screening of
300 colonies derived from control DNA identified 160
clones containing correct APC amplification products,
and none were mutant alleles (0/160 vs. 4/113;
, by Fisher’s exact test). These data establish thatP ! .03
patient 16 DNA contained a small proportion of alleles
from somatic DNA that are identical to the mutant allele
that was responsible for FAP in her daughter. We were
unable to determine the tissue distribution of mosaicism,
because of the death of patient 16 prior to these studies
and because archival paraffin-embedded material had
been infected with mold and was destroyed.
Tailored assays were then designed to detect the levels
of the respective APC mutation (table 1) in the other
four sporadic cases. Preliminary “spiking” experiments
demonstrated that an ∼0.1%mutant-allele presencewas
detectable (data not shown). None of the assays detected
any other cases of parental mosaicism. Parental blood-
leukocyte DNA for patient 148 was analyzed by mu-
tation-specific PCR enrichment; for patient 893, 200 ver-
ified colonies for each sample of parental leukocyteDNA
were screened by single-strand conformation polymor-
phism; for patient 1024, PCR products from single-cell
preparations of 350 paternal lymphocytes and 120
maternal lymphocytes were analyzed by restriction
digestion.
We were surprised to identify a further case of APC
mutational mosaicism, in a proband with FAP. Patient
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Figure 1 S35 sequencing of PCR products from blue and white colonies from patients 16 and 17, showing the presence of mutant (three
GT/CA) and wild-type ( four GT/CA) alleles, respectively (reverse PCR primer was used to sequence).
Figure 2 PCR products of patient 410’s peripheral blood-leu-
kocyte DNA templates digested with DraI, showing readily visible
differences in between wild-type (134-bp) and mutant (112-bp) allele
intensities.
410 has no family history worthy of note but, during
the teenage years, developed orbital rhabdomyosar-
coma, a tumor very rarely associated with FAP (Lynch
et al. 1982; Armstrong et al. 1991). The FAP syndrome
followed an aggressive course, with dense polyposis and
severe desmoid disease. When testing the primers de-
signed for rapid screening of parental PCR clones, by
introduction of a new DraI restriction site into the
4192GrT mutant alleles, we noted a deviation from the
expected heterozygote allele ratio. Replicate experiments
performed on leukocyte DNA after repeated blood sam-
pling consistently showed that the intensity of the mu-
tant allele was less than expected, even after allowance
had been made for the staining intensity of the respective
restriction fragments (fig. 2). PCR products from both
parents and the patient were cloned, and no mutants
were detected in 335 maternal and 210 paternal alleles.
However, there were 98 wild-type and only 38 mutant
alleles identified on analysis of colonies from patient
410, a result significantly different ( ) from theP ! .0003
expected 1:1 ratio but in accordance with the dosimetry
studies using patient 410’s blood-leukocyte DNA tem-
plates (table 2). Twenty-eight undigested alleles were se-
quenced, and all confirmed the presence of a wild-type
TTTAAA DraI restriction site, excluding PCR error as
the explanation for these findings. Sequencing of three
of the clones that did digest with Dra I confirmed the
presence of the mutant allele, as expected. Further con-
firmation that a proportion of circulating leukocytes do
not carry the mutant APC allele was obtained by se-
quencing of PCR products from 18 fresh single-cell lym-
phocyte preparations. Twelve lymphocytes contained ex-
clusively wild-type alleles, whereas the other six showed
mutant and wild-type sequence. These studies show that,
despite the FAP phenotype, patient 410 is mosaic and
does not carry mutant APC in all peripheral blood cells.
We were interested to investigate the tissue distribu-
tion of the mutant and wild-type alleles. Determination
of the level of 4192GrT mutation in a variety of tissues
from patient 410 was possible because surgically re-
sected colon, colonic adenomas, kidney, and orbital
rhabdomyosarcoma were available in paraffin-embed-
ded blocks. When the DraI restriction assay was used,
substantial mutation-level variation between tissues was
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Table 2
Quantitation of Mosaicism for the 4192GrT
Mutant APC Allele in Patient 410
Tissue
Mutant:Wild-Type
Volume Ratioa
Peripheral blood leukocyte .22
Kidney .08
Normal colonic mucosa .44
Rhabdomyosarcoma 1.44
Adenoma 1 .42
Adenoma 2 .28
a Aggregates of three separate assays for each
tissue.
Figure 3 Investigation of dosage of mutant APC allele
(4192GrT) in various tissues from patient 410, with DraI digestion
of PCR products. Control (i.e., nonmutant) leukocyte DNA lacks the
DraI site and so gives a full-length 134-bp fragment onDra I digestion.
Results for two adenomatous colonic polyps (lanes Ad1 and Ad2),
normal colonic mucosa (lane Nm), rhabdomyosarcoma (lane Rm),
renal tissue (lane Kid), and peripheral blood-leukocyte DNA (lane
Leuk) are shown.
noted (fig. 3), with complete absence of the mutant allele
in renal tissue. Dosimetry of bands derived from leu-
kocyte DNA agreed well with the results of prior cloning
studies (table 2). The mutant:normal volume ratio in
rhabdomyosarcoma suggests loss of wild-type allele but
with normal-tissue contamination contributing the faint
normal allele. The microdissected adenomas have mu-
tant:normal volume ratios that are similar to those for
leukocyte DNA, supporting the notion that FAP polyps
can be polyclonal in origin (Novelli et al. 1996).
Genetic instability appears to influence the APC mu-
tation spectrum in colorectal tumors (Huang et al.
1996), and so microsatellite analysis (Farrington et al.
1998) was performed on DNA purified from archival
paraffin-embedded tissues from patients 17 and 410. Pa-
tient 17’s colon tumor showed instability at three of the
four CA-repeat markers analyzed but at none of three
poly-A markers (fig. 4). Although breast cancers rarely
show microsatellite instability (Wooster et al. 1994), we
are not aware of any report describing microsatellite
analysis in colon-tumor tissue from a BRCA1-mutation
carrier. Patient 410’s tumors showed low-level instability
for three CA-repeat markers that gave sufficient data for
analysis (different markers in each tumor), but there was
no poly-A instability. Genomic sequencing of hMSH2
(U03911/U04045 [GenBank]) and hMLH1 (U07343/
U07418 [GenBank]) (Farrington et al. 1998) in patients
16, 17, and 410 did not identify any pathological var-
iants, although hPMS1, hPMS2, and hMSH6 were not
analyzed.
In this study, we have established that combined so-
matic/gonadal mosaicism for an APC mutation can arise
rarely and that a clinical phenotype attributable to that
mutation is not always apparent. In addition, we have
shown germ-line transmission of the mutant allele to
offspring. There may be a phenotypic threshold that is
likely related to both the overall contribution and the
tissue distribution of the mutant allele, as was found in
patient 410. Presumably, the patch size in patient 410
was critically distributed, to allow expression of the FAP
phenotype. There is one other report of a mosaic APC-
gene variant in a patient with FAP (Mandl et al. 1994);
however, this variant was not pathogenic, since it was
incidental to a frameshift APC mutation segregating
with FAP in that family.
Our findings have clinical relevance to counseling re-
garding recurrence risk to siblings of “sporadic” FAP
patients with phenotypically normal parents who do not
appear to carry the APC mutation as assessed by con-
ventional methods. We have shown that gonadal mo-
saicism is a possibility and that therefore the risk to
siblings of an index sporadic case is higher than the
population risk. Somatic mosaicism has been suggested
as a common cause of classic neurofibromatosis 2 (Evans
et al. 1998), and isolated gonadal mosaicism has recently
been demonstrated in tuberous sclerosis (Yates et al.
1997), emphasizing the broader clinical relevance of our
findings. In addition to the implications with regard to
germ-line transmission, somatic mutational mosaicism
of the APC gene has relevance to cancer risk, since APC
plays a pivotal role in neoplastic transformation (Kinzler
and Vogelstein 1996). Individuals may carry, in a small
proportion of epithelial stem cells, a mutant APC allele
that confers an increased cancer risk, even though there
is no obvious evidence of FAP.
We hypothesize that APC mutational mosaicism can
be due to genetic instability and that passage through
the germ line of instability-prone individuals represents
a mechanism by which new mutations might arise. In
this context, the predominance of CA:GT dinucleotide-
repeat instability is noteworthy; and the new germ-line
mutation in patient 17 also arose within a short CA:GT
repeat in APC. Although we did not identify any germ-
line hMSH2 or hMLH1 mutations in patients 16, 17,
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Figure 4 Traces from ABI 310 genetic analyzer with GeneScan
software, showing band shifts between patient 17’s normal-mucosa
DNA template (solid line) and colon-cancer DNA templates (dotted
line), for three CA-repeat markers analyzed. The asterisks (*) indicate
the band shifts observed in the tumor tissue.
or 410, the presence of tumor instability associated with
mosaicism is intriguing. A constitutional mutator phe-
notype due to mismatch repair–gene mutations has been
reported in association with increased mutation rate in
normal tissues (Parsons et al. 1995; Hackman et al.
1997). Indeed, one of these reported patients had clinical
FAP without a detectable heterozygous APC mutation.
Of further interest, a defined MLH1 mutation has been
reported in association with transmission of instability
at the FRAXA locus (Sharrock et al. 1997).
Both the atypical phenotype in these patients and the
association with other molecular events—namely,
BRCA1 mutation and microsatellite instability—is in-
triguing and may reflect an underlying process leading
to genetic instability. Mutation of BRCA1 would not be
expected to induce tumor microsatellite instability, but
we estimate that the probability of the association of
mutations in BRCA1 and APC is 1/10 million (Bisgaard
et al. 1994; Ford et al. 1995), and so a chance occurrence
seems remote in the case reported here. It will be of
interest to determine whether mosaicism for mutations
in other genes is a more general phenomenon than has
been previously recognized.
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HPS Gene Mutations in Hermansky-Pudlak Syndrome
To the Editor:
We recently reported a series of mutations of the HPS
gene in non–Puerto Rican patients with Hermansky-
Pudlak syndrome (MIM 203300) (Oh et al. 1998). One
of these mutations was designated incorrectly in some
places in the article; a frameshift in codon Q397 was
incorrectly designated “E397” in the text (this mutation
is now designated “c1189delC,” in the new nomencla-
ture; Antonarakis 1998). In addition, subsequent to pub-
lication we determined that patient 20 is homozygous
for a novel frameshift due to a single-base deletion in
codon G96, designated “c288delT,” with the first-cousin
parents both being heterozygous for this mutation. Thus,
HPS gene mutations have now been identified in all pa-
tients and families who show apparent linkage to 10q23.
With our original description of the gene (Oh et al. 1996)
and the recent report of Shotelersuk et al. (1998), this
brings the number of reported HPS gene mutations to
11 and further underscores the lack of missense muta-
tions identified in patients with this disorder.
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